[1] Liu WJ, Wu Y, Bi Y, et al. Emerging HxNy influenza A viruses. Cold Spring Harb Perspect Med, 2022; 12, a038406. doi:  10.1101/cshperspect.a038406
[2] Liu WJ, Liu S. A tale of two cities: From influenza HxNy to SARS-CoV-z. China CDC Wkly, 2021; 3, 1052−6. doi:  10.46234/ccdcw2021.256
[3] Asha K, Kumar B. Emerging influenza D virus threat: what we know so far! J Clin Med, 2019; 8, 192. doi:  10.3390/jcm8020192.
[4] Glezen WP, Schmier JK, Kuehn CM, et al. The burden of influenza B: a structured literature review. Am J Public Health, 2013; 103, e43−51. doi:  10.2105/AJPH.2012.301137
[5] Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol, 2018; 16, 47−60. doi:  10.1038/nrmicro.2017.118
[6] Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology, 1990; 175, 59−68. doi:  10.1016/0042-6822(90)90186-u
[7] Vijaykrishna D, Holmes EC, Joseph U, et al. The contrasting phylodynamics of human influenza B viruses. Elife, 2015; 4, e05055. doi:  10.7554/eLife.05055
[8] Caini S, Kusznierz G, Garate VV, et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS One, 2019; 14, e0222381. doi:  10.1371/journal.pone.0222381
[9] Vieira MC, Donato CM, Arevalo P, et al. Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases. Nat Commun, 2021; 12, 4313. doi:  10.1038/s41467-021-24566-y
[10] Edler P, Schwab LSU, Aban M, et al. Immune imprinting in early life shapes cross-reactivity to influenza B virus haemagglutinin. Nat Microbiol, 2024; 9, 2073−83. doi:  10.1038/s41564-024-01732-8
[11] Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis, 2011; 52, 911−6. doi:  10.1093/cid/cir007
[12] Palm AKE, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Front Immunol, 2019; 10, 1787. doi:  10.3389/fimmu.2019.01787
[13] Skowronski DM, Hottes TS, De Serres G, et al. Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Pediatr Infect Dis J, 2011; 30, 833−9. doi:  10.1097/INF.0b013e31822db4dc
[14] Skowronski DM, Hamelin ME, Janjua NZ, et al. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One, 2012; 7, e38929. doi:  10.1371/journal.pone.0038929
[15] Page CK, Shepard JD, Ray SD, et al. Neuraminidase-specific antibodies drive differential cross-protection between contemporary FLUBV lineages. Sci Adv, 2025; 11, eadu3344. doi:  10.1126/sciadv.adu3344
[16] Del Riccio M, Nunes MC, Cowling BJ, et al. Post-disappearance scenarios: policy implications following the potential disappearance of B/Yamagata lineage influenza viruses. Euro Surveill, 2024; 29, 2400196. doi:  10.2807/1560-7917.ES.2024.29.45.2400196
[17] Han W, Zeng J, Shi J, et al. Unraveling the mechanism behind the probable extinction of the B/Yamagata lineage of influenza B viruses. Nat Commun, 2025; 16, 10440. doi:  10.1038/s41467-025-65396-6
[18] Pica N, Chou YY, Bouvier NM, et al. Transmission of influenza B viruses in the guinea pig. J Virol, 2012; 86, 4279−87. doi:  10.1128/JVI.06645-11.
[19] Ran Z, Shen H, Lang Y, et al. Domestic pigs are susceptible to infection with influenza B viruses. J Virol, 2015; 89, 4818−26. doi:  10.1128/JVI.00059-15
[20] Chen Z, Tsui JLH, Gutierrez B, et al. COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses. Science, 2024; 386, eadq3003. doi:  10.1126/science.adq3003
[21] Li J, Huan Y, Xia Q, et al. H3N2 influenza virus characteristics in China (2019–2022): genetic, antigenic, and infection dynamics during the COVID-19 pandemic. Hlife, 2025; 3, 146−58. doi:  10.1016/j.hlife.2025.01.004
[22] Langat P, Raghwani J, Dudas G, et al. Genome-wide evolutionary dynamics of influenza B viruses on a global scale. PLoS Pathog, 2017; 13, e1006749. doi:  10.1371/journal.ppat.1006749
[23] Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol, 2008; 66, 655−63. doi:  10.1007/s00239-008-9119-z
[24] Rosu ME, Kok A, Bestebroer TM, et al. Contribution of neuraminidase to the efficacy of seasonal split influenza vaccines in the ferret model. J Virol, 2022; 96, e01959−21. doi:  10.1128/jvi.01959-21
[25] Zhang X, Ross TM. Anti-neuraminidase immunity in the combat against influenza. Expert Rev Vaccines, 2024; 23, 416−31. doi:  10.1080/14760584.2024.2341538
[26] Wohlbold TJ, Krammer F. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses, 2014; 6, 2465−94. doi:  10.3390/v6062465
[27] Ashraf MA, Raza MA, Amjad MN, et al. A comprehensive review of influenza B virus, its biological and clinical aspects. Front Microbiol, 2024; 15, 1467029. doi:  10.3389/fmicb.2024.1467029
[28] Osterhaus AD, Rimmelzwaan GF, Martina BE, et al. Influenza B virus in seals. Science, 2000; 288, 1051−3. doi:  10.1126/science.288.5468.1051
[29] Song D, Kim H, Na W, et al. Canine susceptibility to human influenza viruses (A/pdm 09H1N1, A/H3N2 and B). J Gen Virol, 2015; 96, 254−8. doi:  10.1099/vir.0.070821-0.
[30] Bedford T, Riley S, Barr IG, et al. Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature, 2015; 523, 217−20. doi:  10.1038/nature14460
[31] Lin Y, He X, Lei W, et al. Cold-chain-based epidemiology: scientific evidence and logic in introduction and transmission of SARS-CoV-2. Glob Transit, 2023; 5, 170−81. doi:  10.1016/j.glt.2023.09.003
[32] Abozeid HH, Gu C, Trifkovic S, et al. Immunity to influenza B/Yamagata-lineage viruses has not waned since the disappearance of this virus lineage. Influenza Other Respir Viruses, 2025; 19, e70188. doi:  10.1111/irv.70188
[33] Desheva Y, Kudar P, Sergeeva M, et al. The persistence of cross-reactive immunity to influenza B/Yamagata neuraminidase despite the disappearance of the lineage: structural and serological evidence. Int J Mol Sci, 2025; 26, 7476. doi:  10.3390/ijms26157476
[34] Barr IG, Subbarao K. Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses. NPJ Vaccines, 2024; 9, 219. doi:  10.1038/s41541-024-01010-y
[35] World Health Organization. Recommendations for influenza vaccine composition for the 2026-2027 northern hemisphere season. https://www.who.int/news/item/27-02-2026-recommendations-for-influenza-vaccine-composition-for-the-2026-2027-northern-hemisphere-season. [2026-03-02].
[36] Liu WJ, Xiao H, Dai L, et al. Avian influenza A(H7N9) virus: from low pathogenic to highly pathogenic. Front Med, 2021; 15, 507−27. doi:  10.1007/s11684-020-0814-5
[37] Li J, Jia T, Yang L. Targeting anti-virulence factor strategies of bacterial pathogens. Biosaf Health, 2025; 7, 1−4. doi:  10.1016/j.bsheal.2025.01.006
[38] Liu WJ, Bi Y, Wang D, et al. On the centenary of the Spanish Flu: being prepared for the next pandemic. Virol Sin, 2018; 33, 463−6. doi:  10.1007/s12250-018-0079-1